Halothane: clinical considerations.
D000769:Anesthesia, Inhalation / Q000009:adverse effects*; D000888:Antibodies, Anti-Idiotypic; D001711:Biotransformation; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000150:complications; D004790:Enzyme Induction; D004802:Eosinophilia / Q000209:etiology; D005334:Fever / Q000209:etiology; D006221:Halothane / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D006505:Hepatitis / Q000517:prevention & control; D006506:Hepatitis A / Q000150:complications; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D008099:Liver / Q000187:drug effects* / Q000276:immunology; D008928:Mitochondria / Q000276:immunology; D011183:Postoperative Complications / Q000401:mortality; D013997:Time Factors; D006113:United Kingdom; D014481:United States
D000888:Antibodies, Anti-Idiotypic; D006221:Halothane